Panama’s Seven Licensees: GMP, Labeling, and Import/Export Rules Before First Medical Cannabis Sales

Panama’s regulated medical market is moving from “policy on paper” to operational reality. After lengthy evaluations under Ley 242 de 2021 and the implementing regulation, Decreto Ejecutivo No. 121 (1 Sept. 2022), Panama’s Ministry of Health (MINSA) has confirmed that seven licenses have been granted—an inflection point that shifts the compliance conversation toward GMP readiness, product authorization, packaging/labeling controls, and import/export execution.

This article summarizes what operators and investors should focus on now: GMP expectations, testing and stability expectations typically required for health-authority oversight, Panama’s product authorization pathway (including the 2025 “exception to sanitary registration” rules), and practical considerations for distribution via pharmacies, prescription workflows, and likely early enforcement priorities.

Focus keyword: Panama medical cannabis licenses 2025

Informational only: This is a high-level compliance explainer, not legal advice. Always confirm details with MINSA/DNFD and qualified counsel.

Regulatory snapshot: what changed between 2021 and 2026

Panama’s framework is anchored by:

• Ley 242 (13 Oct. 2021), published in Gaceta Oficial (and mirrored on MINSA’s norms repository). It establishes the legal basis for regulated medical and therapeutic use, and places health oversight primarily with MINSA and its Dirección Nacional de Farmacia y Drogas (DNFD).

• Official text: https://www.gacetaoficial.gob.pa/pdfTemp/29398_B/GacetaNo_29398b_20211015.pdf

• MINSA mirror: https://www.minsa.gob.pa/sites/default/files/normatividad/ley_242_de_13_de_octubre_de_2021_cannabis.pdf

• Decreto Ejecutivo No. 121 (1 Sept. 2022), the key implementing regulation that operationalizes licensing, handling, controls, and health authority oversight.

• Official publication: https://www.gacetaoficial.gob.pa/pdfTemp/29612_A/GacetaNo_29612a_20220901.pdf

• MINSA norms page: https://www.minsa.gob.pa/normatividad/decreto-ejecutivo-ndeg-121-de-jueves-01-de-septiembre-de-2022-que-reglamenta-la-ley-242

• MINSA/DNFD updates in 2025 focusing on commercialization mechanics—especially product authorization and dispensing rules.

• DNFD Communiqué on prescription and dispensing (Comunicado 025-25): https://dnfd.minsa.gob.pa/sites/default/files/2025-10/COMUNICADO%20025-25%20PRESCRIPCI%C3%93N%20Y%20DISPENSACI%C3%93N%20CANNABIS%20MEDICINAL_0.pdf

• MINSA Resolution establishing requirements for exception to sanitary registration (listed as Resolución No. 212 dated 26 Sept. 2025 on MINSA’s site): https://www.minsa.gob.pa/normatividad/resolucion-ndeg-212-de-viernes-26-de-septiembre-de-2025-por-la-cual-se-establecen-los

Separately, local reporting in early 2026 also indicated that Panama has already seen a first specialized pharmacy open and that MINSA has been publicizing a dedicated DNFD section to centralize information—an indicator that market launch governance is becoming more structured.

Panama’s seven licensees: why “awarded” is not the same as “ready to sell”

Public reporting has identified a group of seven licensed manufacturers, often described as having received authorization after a lengthy evaluation process. While the list of named groups varies by source, the key operational takeaway is consistent: the license is the start of compliance work, not the end.

In Panama’s model, commercialization hinges on three “readiness gates” that tend to slow early rollouts:

1. Facility and QMS readiness (GMP/BPM, documentation, trained staff, controlled warehouses)
2. Product authorization status (full sanitary registration or an allowed exception route, depending on product and phase)
3. Dispensing channel activation (pharmacies authorized, prescription workflow aligned with DNFD guidance, and patient access controls)

For operators, the immediate question is: can you demonstrate pharmaceutical-grade controls and repeatable quality at the level MINSA expects for a tightly controlled product category?

GMP (BPM) expectations: what MINSA is likely to look for

Panama’s DNFD already operates a broader Buenas Prácticas de Manufactura (BPM) inspection and certification program for medicines and related products. Even if the product category is new, the inspection logic is familiar: quality systems, validated processes, controlled environments, and documented evidence.

DNFD also publishes GMP/BPM-related materials that illustrate typical inspection emphasis (e.g., documentation, water/air systems, calibration, cross-contamination controls):

• MINSA BPM training material (example): https://www.minsa.gob.pa/sites/default/files/general/buenas_practicas_de_manufactura_ppt.pdf
• DNFD list of GMP/BPM certificates (program context): https://dnfd.minsa.gob.pa/certificados-de-buenas-pr-cticas

Quality system fundamentals (what “good” looks like)

To prepare for inspections and to reduce batch release delays, manufacturers should expect to evidence:

• Quality management system with defined responsibilities (QA independence, batch release authority)
• Document control: SOP lifecycle, versioning, training linkage, deviation/CAPA linkage
• Supplier qualification for APIs, excipients, packaging components, and critical services
• Change control that treats formulation, process, equipment, and label changes as regulated changes
• Complaint handling and recalls including mock recall capability and traceability depth

Facility & contamination control

Panama’s health-authority expectations will generally align with pharmaceutical norms:

• Segregation to prevent cross-contamination (especially if multiple strengths or product types exist)
• Controlled HVAC where required, with differential pressures and environmental monitoring aligned to risk
• Sanitation programs, cleaning validation where applicable, and pest control
• Water system controls if used in processing/cleaning (specs, sampling, maintenance)

Process validation and batch release discipline

Operational readiness will also be measured by how you handle:

• Master batch records and executed batch records that are complete, contemporaneous, and reviewed
• In-process controls (e.g., blend uniformity, fill volume, weight variation, capsule integrity)
• Packaging line clearance and reconciliation of printed materials
• OOS/OOT investigations and scientifically justified disposition decisions

Testing specifications: potency, contaminants, and “fit-for-purpose” methods

Panama’s published public-facing documents focus more on authorization and dispensing controls than granular analytical monographs. That said, for MINSA-facing submissions and batch release, manufacturers should be ready to support a specification package that is consistent with pharmaceutical quality and the risk profile of the dosage form.

A practical approach is to design a specification set that includes:

Identity and potency (content/label claim)

• Identity of key constituents
• Assay for declared active constituents (content uniformity where applicable)
• Impurities profile appropriate to extract/process route

Microbiology (particularly for non-sterile oral forms)

• Total aerobic microbial count, yeast/mold, and objectionable organisms aligned to dosage form risk

Chemical contaminants

• Residual solvents (if extraction uses solvents)
• Pesticides (especially if plant-derived inputs are used)
• Heavy metals
• Mycotoxins where risk-justified

Method validation package

MINSA will expect confidence that analytical results are meaningful. Ensure:

• Methods are validated for specificity, accuracy, precision, linearity, range, robustness
• Reference standards are controlled (qualification, CoAs)
• Sampling plans and retain samples are defined

Business takeaway: Even before “first sales,” delays often come from incomplete analytical validation or an inability to defend specs scientifically. Build your stability and method validation timelines into launch planning.

Stability data: shelf-life, storage, and packaging compatibility

One of the most common “hidden blockers” in new medical markets is stability. Health authorities want to know: will the product remain within specification throughout its shelf life in the intended packaging under real distribution conditions?

Manufacturers should be prepared to provide:

• Accelerated and long-term stability studies
• Stability-indicating methods (assay and degradants)
• Microbial stability (if applicable)
• In-use stability where relevant (e.g., multi-dose oils)
• Packaging compatibility justification (leachables/extractables risk assessment for droppers, liners, plastics)

Also ensure your labels align to stability outcomes:

• Storage conditions (temperature, light, humidity)
• Beyond-use guidance once opened, if applicable
• Clear expiry date format and lot/batch identification

Packaging and labeling: health-authority mindset and what to prioritize

Panama’s DNFD emphasis on controlled dispensing and health oversight implies that packaging and labeling will be treated like a pharmaceutical control, not a lifestyle brand canvas.

Even where specific label text is defined in product authorization requirements, operators should anticipate strict review of:

Core label elements (expect these to be non-negotiable)

• Product name and dosage form
• Strength/concentration and net content
• Lot/batch number, manufacture date, and expiry date
• Manufacturer and responsible party information
• Storage conditions
• Directions for use consistent with authorized indications and prescribing norms
• Warnings and contraindication-style statements appropriate to controlled medical use

Anti-youth-appeal and claim discipline

Early enforcement typically targets “soft” violations that are easy to prove:

• Youth appeal cues (cartoon imagery, candy-like presentations, playful flavors marketed toward minors)
• Unapproved claims (cure claims, broad disease claims, “miracle” language)
• Digital marketing that resembles consumer packaged goods promotion rather than health-professional communication

If your labeling or website content implies treatment for specific diseases beyond what the product authorization supports, you create a direct enforcement hook.

Product authorization in practice: sanitary registration vs. “exception” route

A key 2025 development is MINSA’s publication of requirements for excepción al registro sanitario (exception to sanitary registration) for products containing medical cannabis and derivatives.

• MINSA Resolution page: https://www.minsa.gob.pa/normatividad/resolucion-ndeg-212-de-viernes-26-de-septiembre-de-2025-por-la-cual-se-establecen-los

Media coverage (including TVN) described the resolution as setting documentation requirements for finished products, and emphasized that dispensing is tied to authorized patients and prescriptions by qualified physicians.

How to think about it operationally:

• Full sanitary registration is the “classic” pathway used for medicines.
• The exception pathway is a pragmatic bridge that can allow early access while the market builds full registration capacity—yet it is still documentation-heavy and compliance-sensitive.

“Lot notification” and batch-level controls

While Panama’s public-facing documents do not always use the same terminology as other jurisdictions, the regulatory intent is clear: DNFD wants traceability and the ability to act quickly if there is a quality or diversion issue.

Expect operational demands such as:

• Clear batch/lot traceability from production through pharmacy dispensing
• Retain sample management
• Ability to rapidly provide COAs and release documentation for any batch on the market
• Distribution records that support targeted recalls

Import/export and re-export: permitting discipline and shipment-by-shipment governance

Panama’s legal framework contemplates import, export, and re-export of medical cannabis products under health authority control.

Two points matter for compliance planning:

1. Only properly authorized entities can import and export under the framework (typically tied to the manufacturing license / operational authorization).
2. Export permissions are not “set and forget.” In tightly controlled categories, authorities generally require shipment-specific documentation.

Industry compliance summaries have noted that Panama’s authorization model includes obtaining export documentation for each shipment and operating under broader controlled-substances rules (supplemented by other Panamanian laws referenced in commentary). Treat this as a strong signal that your logistics team must be compliance-trained, not just freight-trained.

Practical import readiness checklist

Before the first import of active ingredients, intermediates, or finished goods, build a dossier that typically includes:

• Proof of license/authorization and facility address consistency
• Supplier GMP evidence and quality agreement
• Product composition and specification package
• Security plan for transport and storage (chain-of-custody)
• Customs broker alignment on tariff codes and controlled shipment procedures

Practical export readiness checklist

For exports, be prepared to show:

• Product authorization status (or permitted exception status)
• Batch release documentation and COA
• Import authorization from the destination country (often required in controlled categories)
• Evidence that the receiving party is authorized in its jurisdiction

Watch item: cross-border e-commerce and courier shipments

One of the fastest ways to trigger enforcement is informal cross-border shipping through consumer-style channels:

• “Direct-to-patient” cross-border sales
• Social-media driven orders shipped via standard courier without controlled shipment permitting

Panama’s early enforcement priorities are likely to include stopping unauthorized online sales and preventing diversion, because these are high-visibility and politically sensitive.

Distribution channel design: pharmacies at the center, not open retail

Panama’s emerging model is strongly pharmacy-oriented. DNFD’s communiqué on prescription and dispensing is explicit that products must be dispensed in authorized pharmacies under medical prescription requirements.

• DNFD Comunicado 025-25 (prescription/dispensing): https://dnfd.minsa.gob.pa/sites/default/files/2025-10/COMUNICADO%20025-25%20PRESCRIPCI%C3%93N%20Y%20DISPENSACI%C3%93N%20CANNABIS%20MEDICINAL_0.pdf

Pharmacies vs. clinics: what to expect

In many Latin American medical frameworks, the clinic/physician is the prescriber and treatment monitor, while the pharmacy is the controlled dispensing point. That means:

• Clinics may educate and prescribe, but dispensing is likely limited to DNFD-authorized pharmacies (including possibly specialized pharmacies).
• Pharmacies must implement storage controls, prescription verification, and recordkeeping.

Prescription systems: patient eligibility and traceability

Public reporting around the 2025 resolution suggested products may be dispensed only to patients listed under a national program and only with prescription by an authorized physician.

Operational impacts:

• Manufacturers must ensure their distribution partners can handle restricted patient access processes.
• Pharmacies must be trained on acceptable prescriptions, refills (if allowed), and recordkeeping.

Anticipated enforcement priorities in Panama’s first commercialization wave

In first-launch medical markets, regulators often prioritize areas that are:

• easy to audit,
• tied to public safety, and
• visible to the public.

Based on MINSA/DNFD posture and common early-market patterns, anticipate focus on:

H3: Claims and promotional materials

• Disease claims beyond authorization
• Testimonials and influencer marketing that looks like consumer advertising
• Lack of prior approvals for certain health-related promotional materials (Panama has broader advertising controls for health products via MINSA processes)

H3: Youth appeal and “consumerization”

• Packaging that resembles candy/snacks
• Flavor-forward marketing designed to broaden to non-medical consumers

H3: Pharmacy compliance

• Dispensing without proper prescription
• Dispensing outside authorized locations
• Inadequate storage/security or missing records

H3: Import/export documentation and diversion controls

• Missing shipment documentation
• Mismatched quantities vs. permits
• Unreported losses/thefts

What businesses should do now (90-day operational plan)

For licensees and supply-chain partners aiming to be ready for first sales, prioritize the following workstreams:

1) Close GMP gaps with a regulator-ready evidence pack

• Internal audit against DNFD BPM expectations
• CAPA plan with owners and dates
• Validate critical processes and cleaning
• Build a complete batch record and QA release workflow

2) Lock the analytical program

• Finalize specs and validated methods
• Qualify labs and reference standards
• Establish retain samples and stability program

3) Treat labeling like a regulated control, not a marketing asset

• Label review committee (QA + Regulatory + Medical)
• Website and social content review for implied claims
• Packaging controls (artwork versioning, reconciliation)

4) Operationalize import/export permitting

• Compliance-trained logistics SOPs
• Broker SOP alignment and shipment checklists
• Destination market due diligence (authorized recipient proof)

5) Build pharmacy channel readiness

• Authorized pharmacy onboarding
• Training: storage, dispensing workflow, adverse event escalation
• Recall communications protocol with pharmacies

What patients and the public should expect

As Panama’s first products reach pharmacies, expect:

• Prescription-only access
• Limited early SKU breadth (often oils/oral forms first)
• Stronger emphasis on controlled dispensing than on broad retail availability
• Gradual expansion as more products obtain authorization and as prescribing confidence grows

Key takeaways for “Panama medical cannabis licenses 2025” stakeholders

• Panama’s seven licenses signal market momentum, but GMP, product authorization, and pharmacy dispensing controls determine who launches successfully.
• The 2025 MINSA resolution on exception to sanitary registration is a pivotal bridge mechanism—yet it still requires a serious documentation package and disciplined labeling/claims.
• Import/export is likely to be shipment-governed with tight chain-of-custody expectations; informal e-commerce distribution is a high-risk enforcement target.

Stay audit-ready with CannabisRegulations.ai

Launching into a new medical market is a documentation marathon: SOPs, stability programs, labeling governance, import/export checklists, and pharmacy channel controls.

Use https://cannabisregulations.ai for practical tools and updates to support cannabis compliance, licensing, and regulations—including readiness checklists for dispensary rollout and controlled medical distribution models.